+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Tinnitus - Pipeline Insight, 2022

  • PDF Icon

    Drug Pipelines

  • 60 Pages
  • March 2022
  • Region: Global
  • DelveInsight
  • ID: 5534167
The publisher’s, “Tinnitus - Pipeline Insight, 2022,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Tinnitus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Tinnitus Understanding


Tinnitus: Overview

Tinnitus is commonly described as a ringing in the ears, but it also can sound like roaring, clicking, hissing, or buzzing. It may be soft or loud, high pitched or low pitched. Tinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. The most common associated symptoms or subjective discomforts involve concentration difficulties, insomnia, and decreased speech discrimination. Tinnitus does not represent a disease itself but instead is a symptom of a variety of underlying diseases. Otologic causes include noise-induced hearing loss, presbycusis, otosclerosis, otitis, impacted cerumen, sudden deafness, Meniere's disease, and other causes of hearing loss. The most effective treatment for tinnitus is to work on the underlying cause. The underlying cause can be treatable by medical and/or surgical treatment. Approaches for tinnitus management and treatment include medications, vitamin therapy, biofeedback, hypnosis, electrical stimulation, relaxation therapy, counselling, habituation therapies, tinnitus retraining therapy [TRT], cognitive behavioural therapy [CBT], tinnitus maskers and hearing aid.

'Tinnitus - Pipeline Insight, 2022' report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tinnitus pipeline landscape is provided which includes the disease overview and Tinnitus treatment guidelines. The assessment part of the report embraces, in depth Tinnitus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tinnitus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Tinnitus R&D. The therapies under development are focused on novel approaches to treat/improve Tinnitus.

Tinnitus Emerging Drugs Chapters

This segment of the Tinnitus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tinnitus Emerging Drugs


AM-101: Auris Medical

AM-101 is an NMDA receptor antagonist that is being developed for treatment of acute inner ear tinnitus. The NMDA (N-methyl-D-aspartate) receptor is a glutamate receptor on the neuron leading to the auditory cortex that is communicated to by the hair cells of the inner ear. The drug is in Phase III clinical development for the treatment of Tinnitus.

OTO-313: Otonomy

OTO-313 is a sustained-exposure formulation of the potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine. It is believed that gacyclidine can reduce the severity of tinnitus symptoms following cochlear injury by decreasing the over-activation of damaged auditory nerve fibers in the cochlea and their connections. OTO-313 utilizes a novel, patent-protected formulation technology to provide several weeks of gacyclidine drug exposure in the inner ear following a single intratympanic injection. In 2020, positive results were reported from a Phase I/II trial of OTO-313 in patients with unilateral tinnitus of at least moderate severity. A Phase II trial is currently underway with results expected in mid-2022. In November 2014, Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus.

Further product details are provided in the report……..

Tinnitus: Therapeutic Assessment

This segment of the report provides insights about the different Tinnitus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Tinnitus

There are approx. 8+ key companies which are developing the therapies for Tinnitus. The companies which have their Tinnitus drug candidates in the most advanced stage, i.e. Phase III include, Auris Medical.

Phases


The publisher’s report covers around 8+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration


Tinnitus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tinnitus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tinnitus therapeutic drugs key players involved in developing key drugs.

Tinnitus Report Insights

  • Tinnitus Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Tinnitus Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Tinnitus drugs?
  • How many Tinnitus drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tinnitus?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tinnitus therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Tinnitus and their status?
  • What are the key designations that have been granted to the emerging drugs?

Table of Contents

IntroductionExecutive Summary
Tinnitus: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)
  • Comparative Analysis

AM-101: Auris Medical
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Mid Stage Products (Phase II)
  • Comparative Analysis

OTO-313: Otonomy
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Preclinical stage products
  • Comparative Analysis

GW-TT1: Gateway Biotechnology
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Inactive Products
  • Comparative Analysis
  • Tinnitus Key Companies
  • Tinnitus Key Products
  • Tinnitus- Unmet Needs
  • Tinnitus- Market Drivers and Barriers
  • Tinnitus- Future Perspectives and Conclusion
  • Tinnitus Analyst Views
  • Tinnitus Key Companies
  • Appendix

List of Tables
Table 1 Total Products for Tinnitus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Tinnitus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Otonomy
  • Auris Medical
  • Gateway Biotechnology
  • Cognosetta
  • Knopp Biosciences
  • Otologic Pharmaceutics
  • Decibel therapeutics
  • AudioCure Pharma